Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development? by Ferrara, Christine Therese et al.
UCSF
UC San Francisco Previously Published Works
Title
Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development?
Permalink
https://escholarship.org/uc/item/8dr1q5q8
Journal
Diabetes care, 40(5)
ISSN
0149-5992
Authors
Ferrara, Christine Therese
Geyer, Susan Michelle
Liu, Yuk-Fun
et al.
Publication Date
2017-05-01
DOI
10.2337/dc16-2331
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Excess BMI in Childhood:
A Modifiable Risk Factor for
Type 1 Diabetes Development?
Diabetes Care 2017;40:698–701 | DOI: 10.2337/dc16-2331
OBJECTIVE
We aimed to determine the effect of elevated BMI over time on the progression to
type 1 diabetes in youth.
RESEARCH DESIGN AND METHODS
Westudied1,117 children in theTrialNet Pathway toPrevention cohort (autoantibody-
positive relatives of patientswith type 1 diabetes). Longitudinally accumulated BMI
above the 85th age- and sex-adjusted percentile generated a cumulative excess
BMI (ceBMI) index. Recursive partitioning and multivariate analyses yielded sex-
and age-specific ceBMI thresholds for greatest type 1 diabetes risk.
RESULTS
Higher ceBMI conferred significantly greater risk of progressing to type 1 diabetes.
The increased diabetes risk occurred at lower ceBMI values in children <12 years
of age compared with older subjects and in females versus males.
CONCLUSIONS
Elevated BMI is associated with increased risk of diabetes progression in pediatric
autoantibody-positive relatives, but the effect varies by sex and age.
Studies report conflicting data regarding the roles of weight and obesity on type 1
diabetes risk (1–5). Most studies limit analyses to BMI at a single time point prior to
diabetes diagnosis. Further, the influence of sex and age remain unexplored. We
evaluated the longitudinal influence of cumulative excess BMI (ceBMI), a calculated
aggregate measure of BMI elevation over time, on progression to type 1 diabetes in
children of the TrialNet Pathway to Prevention (PTP) cohort.
RESEARCH DESIGN AND METHODS
The TrialNet PTP study screened 3,285 individuals from March 2004 to June
2014 and monitored them for progression to diabetes through November
2015 (6). This analysis included participants aged 2–18 years at their first BMI
evaluation with$2 BMI measurements before 20 years of age (n5 1,117). Baseline
was defined as the first visit with a BMI evaluation.
Standard protocol oral glucose tolerance test and HbA1c were obtained at each
visit (7). Diabetes was diagnosed according to American Diabetes Association crite-
ria (8). HbA1c $6.5% was part of confirmatory testing (9).
BMI was calculated as weight (kg)/height (m2). ceBMI was adopted to measure
persistent BMI elevation$85th percentile for age- and sex-adjusted BMI. Weighted
sums of the differences between actual BMI and the corresponding 85th percentile
at each BMI assessment were calculated (10,11) and then further annualized to
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accommodate irregular timing of BMI
assessment in relation to time to diabetes
or censoring (for calculation of ceBMI, see
Supplementary Data). For individuals
who progressed to diabetes, the last
BMI used was $6 months prior to diag-
nosis date.
Statistical Considerations
Pearson x2 tests, Fisher exact tests,
Wilcoxon rank-sum tests, Kruskal-Wallis
tests, and nonparametric Spearman
rank correlation tests were used as ap-
propriate. Analyses of BMI were based
on relevant Centers for Disease Control
and Prevention cutoffs (www.cdc.gov/
nccdphp/dnpao/growthcharts/resources/
sas.htm). ceBMI was analyzed as both a
continuous measure and a dichoto-
mized measure. ceBMI $0 indicated
that an individual’s average BMI was
$85th age- and sex-adjusted percentile
during the observation period.
The primary outcome was time to
type 1 diabetes (i.e., time from first
BMI evaluation to date of diagnosis).
Those not diagnosed with type 1 diabe-
tes were censored at their last follow-up
or enrollment in a prevention trial.
Kaplan-Meier methods assessed distri-
bution differences in the time to type 1
diabetes among groups, and Cox propor-
tional hazardsmodels evaluated the influ-
ence of continuous and categorical
variables. Assumptions for proportional-
ity of hazards were tested. All time-to-
event analyses were adjusted for age,
sex, and antibody number confirmed at
screening (single vs. multiple). Additional
adjustment for thepresenceof thehighest-
risk HLA genotype (i.e., DR3-DQ2/DR4-
DQ8) did not alter significance of the
results. Recursive partitioning analysis
was used to identify critical cut points
for ceBMI and age at first BMI evaluation
for influence on diabetes development
and risk stratification of time-to-event
(12) (rpart package in R).
Inferential tests were two-sided. Any
P values ,0.05 (0.1 for interaction
terms) were considered significant. All
analyses were conducted in R (version
3.1.2; Windows; Microsoft).
RESULTS
We analyzed a total of 1,117 pediatric
subjects of the PTP cohort between
the ages of 2 and 18 years (median:
10.1 years; interquartile range [IQR]:
6.7–13.3 years), of whom 20% (n 5
220) developed diabetes. Median first
BMI percentile was 63.8% (IQR: 36.6–
84.8%), with 14% overweight (BMI
$85th to ,95th percentile) and 11%
obese ($95th percentile). ceBMI ranged
from 210 to 15.1 kg/m2 (median:
21.86 kg/m2; IQR:23.6 to20.03 m2/kg).
Nearly 25% of subjects had ceBMI
values$0 kg/m2 representing sustained
excess BMI above the Centers for Dis-
ease Control and Prevention thresholds
of overweight/obesity (Supplementary
Table 1).
Higher ceBMI was associated with
significantly greater risk of progression
to type 1 diabetes, which persisted after
adjusting for age at first BMI evaluation,
antibody number, and sex. For each
1-kg/m2 increase in ceBMI, there was a
6.3% increased relative risk of type 1 di-
abetes progression (hazard ratio [HR]:
1.063 [95% CI 1.03–1.10]; P 5 0.0006).
Individuals who, on average, were persis-
tently overweight or obese (ceBMI $0)
had a 63% greater type 1 diabetes risk,
adjusted for age, sex, and antibody num-
ber (HR: 1.63 [95% CI: 1.22–2.18]; P 5
0.0009).
Age at baseline was a significant in-
dependent risk factor for type 1 diabe-
tes progression (HR: 0.94; P 5 0.0006),
adjusted for ceBMI, sex, and antibody
status. A significant interaction between
age and sex together with ceBMI in rela-
tion to time to diabetes (P 5 0.072) trig-
gered investigation of age- and sex-specific
strata. By recursive partitioning algorithms,
we first identified 12 years as the age cut
point that best discriminated risk for type 1
diabetes progression for the combined
cohort and for males or females indepen-
dently. Recursive partitioning analysis as
well asmultivariablemodel-baseddiagnos-
tics identified cut points for ceBMI that
best differentiated risk for disease progres-
sion (ceBMI diabetes risk threshold). The
ceBMI diabetes risk threshold was lower
in children ,12 years, regardless of sex
(21.4 kg/m2), than in older children
(4.6 kg/m2). That is, the increase in type 1
diabetes risk occurs at lower levels of sus-
tained excess BMI in younger children.
Males overall had a higher ceBMI dia-
betes risk threshold influencing progres-
sion to type 1 diabetes than females,
suggesting an increased sensitivity to
BMI in female subjects. Males$12 years
of age were least affected by ceBMI and
had a risk threshold (5 kg/m2) much
higher than the threshold defining
overweight/obese. In contrast, females
,12 years old appeared to be most influ-
enced by body weight, as the ceBMI risk
threshold was 21.35 kg/m2, suggesting
that BMI percentiles below the over-
weight/obese threshold still increase
type 1 diabetes risk in this subgroup
(Fig. 1).
CONCLUSIONS
Our study is the first to apply ceBMI
methodology to type 1 diabetes, and re-
sults support that sustained elevation of
BMI is associated with type 1 diabetes
progression, with effects varying by sex
and age. Older age diluted the effect of
elevated BMI on type 1 diabetes pro-
gression as seen by a lower ceBMI dia-
betes risk threshold in individuals
,12 years old compared with those
$12 years old. This age-dependent
effect of sustained excess BMI on
type 1 diabetes progression is present
in both sexes, but females were more
sensitive to the effect of elevated
BMI.
These findings lend insight into prior
studies that reported inconsistent re-
sults of the effects of BMI on type 1 di-
abetes risk (2–5). Beyond incorporation
of longitudinal data, ceBMI measure-
ment offers the additional advantage
of an unrestricted upper limit compared
with BMI percentile and may offer
greater resolution than BMI Z-score.
Limitations include the lack of Tanner
staging and sex hormone measure-
ments that could elucidate mechanisms
of the identified age- and sex-specific
ceBMI diabetes risk thresholds. Our
study was not designed to specifically
address the effects of acute changes in
BMI on disease onset, and the small
number of diabetes events in some
age and sex strata further hindered
this ability. Finally, we investigated an
at-risk cohort of autoantibody-positive
relatives of patients with type 1 diabe-
tes; although this cohort was heteroge-
neous, the results may not be broadly
applicable to the general population.
Our results indicate that sustained ele-
vation of BMI is associatedwith increased
progression to type 1 diabetes in an
at-risk pediatric population and that the
BMI 85th percentile may not appropri-
ately differentiate this risk for all pediatric
subjects. Our data suggest that lifestyle
modifications may delay disease onset
in an at-risk population and suggest
care.diabetesjournals.org Ferrara and Associates 699
Figure 1—Effect of ceBMI on type 1 diabetes risk comparing traditional overweight/obese ceBMI definitions to age- and sex-specific ceBMI diabetes
risk thresholds. Proportion type 1 diabetes–free pediatric subjects of the PTP cohort according to age ($12 vs.,12 years old) and sex strata (males
vs. females). A, C, E, and G: Assessment of overweight/obese threshold based on the 85th percentile for age- and sex-adjusted BMI. Dotted lines
indicate ceBMI $0 (overweight/obese); solid gray indicates ceBMI ,0 (nonoverweight/obese). B, D, F, and H: Assessment of ceBMI diabetes risk
thresholds identified by recursive partitioning. Dotted lines indicate greater than or equal to age- and sex-specific ceBMI diabetes risk threshold;
solid gray indicates less than age- and sex-specific ceBMI diabetes risk threshold. All models adjusted for antibody number (single vs. multiple).
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age- and sex-specific ceBMI thresholds to
implement such changes.
Funding. The sponsor of the trialwas the Type 1
Diabetes TrialNet PTP Study Group. The Type 1
Diabetes TrialNet PTP Study Group is a clinical
trials network funded by the National Institutes
of Health through the National Institute of Di-
abetes and Digestive and Kidney Diseases, the
National Institute of Allergy and Infectious Dis-
eases, and the Eunice Kennedy Shriver National
Institute of Child Health and Human Develop-
ment, through the cooperative agreements
U01-DK-061010, U01-DK-061034, U01-DK-
061042, U01-DK-061058, U01-DK-085465,
U01-DK-085453, U01-DK-085461, U01-DK-
085463, U01-DK-085466, U01-DK-085499,
U01-DK-085504, U01-DK-085505, U01-DK-
085509, U01-DK-103180, U01-DK-103153,
U01-DK-085476, and U01-DK-103266 and
JDRF. This work was also partially supported
by National Institutes of Health grants K12-DK-
094726 (to C.T.F.) and U01-DK-103180-01 (to
M.J.R.).
The contents of this article are solely the
responsibility of the authors and do not neces-
sarily represent the official views of the National
Institutes of Health or JDRF.
Duality of Interest. No potential conflicts of
interest relevant to this article were reported.
Author Contributions. C.T.F. designed the
analysis and study design, researched data,
and wrote the manuscript. S.M.G. analyzed the
data, contributed statistical support, and contrib-
uted to the writing of the manuscript. Y.-F.L.,
C.E.-M., I.M.L., R.B., D.J.B., H.R., A.M., andS.E.G.
reviewed and edited the manuscript and contrib-
uted to the discussion. M.J.R. contributed to the
data analysis design and interpretation of results
and critically revised the manuscript. All authors
aremembers of the Type 1 Diabetes TrialNet Study
Group. M.J.R. is the guarantor of this work and, as
such, had full access to all the data in the study and
takes responsibility for the integrity of the data and
the accuracy of the data analysis.
Prior Presentation. Parts of this study were
presented in abstract form at the 76th Scientific
Sessions of the American Diabetes Association,
New Orleans, LA, 10–14 June 2016.
References
1. Wilkin TJ. The accelerator hypothesis: weight
gain as the missing link between type I and
type II diabetes. Diabetologia 2001;44:914–922
2. Elding Larsson H, Vehik K, Haller MJ, et al.;
TEDDY Study Group. Growth and risk for islet
autoimmunity and progression to type 1 diabe-
tes in early childhood: the Environmental Deter-
minants of Diabetes in the Young Study.
Diabetes 2016;65:1988–1995
3. Meah FA, DiMeglio LA, Greenbaum CJ, et al.;
Type 1 Diabetes TrialNet Study Group. The re-
lationship between BMI and insulin resistance
and progression from single to multiple autoan-
tibody positivity and type 1 diabetes among
TrialNet Pathway to Prevention participants.
Diabetologia 2016;59:1186–1195
4. Kuchlbauer V, Vogel M, Gausche R, et al. High
birth weights but not excessive weight gain prior
to manifestation are related to earlier onset of
diabetes in childhood: ‘accelerator hypothesis’ re-
visited. Pediatr Diabetes 2014;15:428–435
5. Sosenko JM, Krischer JP, Palmer JP, et al.;
Diabetes Prevention Trial–Type 1 Study Group.
A risk score for type 1 diabetes derived from
autoantibody-positive participants in the Diabe-
tes Prevention Trial–Type 1. Diabetes Care
2008;31:528–533
6. Greenbaum CJ, Mandrup-Poulsen T, McGee
PF, et al.; Type 1 Diabetes Trial Net Research
Group; European C-Peptide Trial Study Group.
Mixed-meal tolerance test versus glucagon
stimulation test for the assessment of beta-
cell function in therapeutic trials in type 1 di-
abetes. Diabetes Care 2008;31:1966–1971
7. Sosenko JM, Mahon J, Rafkin L, et al.; Diabe-
tes Prevention Trial-Type 1 and TrialNet Study
Groups. A comparison of the baseline metabolic
profiles between Diabetes Prevention Trial-
Type 1 and TrialNet Natural History Study par-
ticipants. Pediatr Diabetes 2011;12:85–90
8. American Diabetes Association. Standards of
medical care in diabetesd2014. Diabetes Care
2014;37(Suppl. 1):S14–S80
9. Skyler JS, Greenbaum CJ, Lachin JM, et al.;
Type 1Diabetes TrialNet StudyGroup. Type 1Di-
abetes TrialNet–an international collaborative
clinical trials network. Ann N Y Acad Sci 2008;
1150:14–24
10. Lee JM, Gebremariam A, Vijan S, Gurney JG.
Excess body mass index-years, a measure of de-
gree and duration of excess weight, and risk for
incident diabetes. Arch Pediatr Adolesc Med
2012;166:42–48
11. Bouchard DR, Porneala B, Janssen I, et al. Risk
of type 2 diabetes and cumulative excess weight
exposure in the Framingham Offspring Study.
J Diabetes Complications 2013;27:214–218
12. Xu P, Krischer JP; Type 1 Diabetes TrialNet
Study Group. Prognostic classification factors
associated with development of multiple auto-
antibodies, dysglycemia, and type1diabetesda re-
cursive partitioning analysis. Diabetes Care 2016;
39:1036–1044
care.diabetesjournals.org Ferrara and Associates 701
